Johnson & Johnson Asia Pacific Pte Ltd today announced the official opening of its new Asia Pacific headquarters. The new 15,800 sq. meter facility will bring together more than 1,000 employees from Johnson & Johnson’s pharmaceuticals, medical devices and consumer businesses in one single location to spearhead new ideas and frameworks for healthcare of the future. The headquarters will boast a Design Lab, Leadership Lab, and Human Performance Institute. Johnson & Johnson’s Asia Design Lab will be the first design lab outside of the United States. Singapore has also been selected as the location for Johnson & Johnson’s first global development center known as the Leadership Lab, said a J&J press release. The Leadership Lab aims to conduct over 200 leadership development classes and train 4,000 Asian leaders annually. As a think-tank, the Leadership Lab will create links with universities, research groups, governments, healthcare organizations and other partners to co-create new healthcare models and solutions to prototype capabilities required to author the next chapter of healthcare innovation in Asia. The regional headquarters will also include Asia Pacific’s first Human Performance Institute (HPI), offering proprietary leadership development initiatives to participants outside of Johnson & Johnson, with the goal to train 150,000 people in Singapore by 2020.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.